Citations

Clear

3030 citation(s) found for "Susan, M".

Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies
Lee, Alice W. , Rosenzweig, Stacey, Wiensch, Ashley , Group, the Australian Ovarian Cancer Study, Ramus, Susan J. , Menon, Usha , Ziogas, Argyrios , Anton‐Culver, Hoda , Whittemore, Alice S. , Sieh, Weiva , Rothstein, Joseph H. , McGuire, Valerie, Wentzensen, Nicolas , Qin, Bo , Terry, Kathryn L. , Titus, Linda , Schildkraut, Joellen M. , Goode, Ellen L. , Jordan, Susan J. , Ness, Roberta B., Moysich, Kirsten B. , Thompson, Pamela J., Goodman, Marc T. , Carney, Michael E. , Chang‐Claude, Jenny , Rossing, Mary Anne, Khoja, Lilah , Alimujiang, Aliya , Phung, Minh Tung , Brieger, Katharine K. , Wu, Anna H. , Pike, Malcolm C. , Webb, Penelope M. , Pearce, Celeste Leigh , Ramus, Susan J , Webb, Penelope M , Menon, Usha , Anton-Culver, Hoda , Moysich, Kirsten , Sieh, Weiva , Ziogas, Argyrios , Qin, Bo , Khoja, Lilah , Goodman, Marc T , Group, the Australian Ovarian Cancer Study, Gentry‐Maharaj, Aleksandra , Bandera, Elisa V. , Cramer, Daniel W. , Berchuck, Andrew , Kjær, Susanne K. , Jensen, Allan , Modugno, Francesmary , Harris, Holly R. , Doherty, Jennifer A. , Risch, Harvey A. , Mukherjee, Bhramar , Pharoah, Paul D.P. , Phung, Minh Tung

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 4, 2020 | Volume: 113 | Issue: 3 | Pages: 301-308

10.1093/jnci/djaa099 | PMID 32766851 Get It

Abstract Background Parity is associated with decreased risk of invasive ovarian cancer; however, the relationship between incomplete pregnancies and invasive ovarian cancer risk is unclear. This relationship was examined using 15 case-control studies from the Ovarian Cancer Association Consortium (OCAC). Histotype-specific associations, which have not been examined previously with large sample sizes, were also evaluated. Methods A pooled analysis of 10 470 invasive epithelial ovarian cancer cases and 16 942 controls was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between incomplete pregnancies and invasive epithelial ovarian cancer were estimated using logistic regression. All models were conditioned on OCAC study, race and ethnicity, age, and education level and adjusted for number of complete pregnancies, oral contraceptive use, and history of breastfeeding. The same approach was used for histotype-specific analyses. Results Ever having an incomplete pregnancy was associated with a 16% reduction in ovarian cancer risk (OR = 0.84, 95% CI = 0.79 to 0.89). There was a trend of decreasing risk with increasing number of incomplete pregnancies (2-sided Ptrend < .001). An inverse association was observed for all major histotypes; it was strongest for clear cell ovarian cancer. Conclusions Incomplete pregnancies are associated with a reduced risk of invasive epithelial ovarian cancer. Pregnancy, including incomplete pregnancy, was associated with a greater reduction in risk of clear cell ovarian cancer, but the result was broadly consistent across histotypes. Future work should focus on understanding the mechanisms underlying this reduced risk.
Mucosal Inflammatory and Wound Healing Gene Programmes Reveal Targets for Stricturing Behaviour in Paediatric Crohn’s Disease
Haberman, Yael , Minar, Phillip , Ghandikota, Sudhir , Tegge, Samuel , Shapiro, Daniel , Shuler, Brianne , Braun, Tzipi, Ta, Allison , Walters, Thomas D. , Baldassano, Robert N. , Noe, Joshua D. , Rosh, Joel R. , Markowitz, James , Dotson, Jennifer L. , Mack, David , Heyman, Melvin B. , Baker, Susan S. , Moulton, Dedrick E., Patel, Ashish , Gulati, Ajay , Steiner, Steven J. , LeLeiko, Neal S. , Otley, Anthony , Ziring, David , Gokhale, Ranjana , Kim, Sandra , Guthery, Stephen L. , Cohen, Stanley A. , Aronow, Bruce J. , Stephens, Michael C., Gibson, Greg , Dubinsky, Marla, Hyams, Jeffrey S. , Jegga, Anil G. , Denson, Lee A. , Stephens, Michael, Leleiko, Neal S , Karns, Rebekah A. , Dexheimer, Phillip J. , Shapiro, Daniel, Venkateswaran, Suresh , Kellermayer, Richárd , Griffiths, Anne Marie , Oliva‐Hemker, Maria , Snapper, Scott B. , Dillman, Jonathan R , Kugathasan, Subra

Mayo Clinic

Journal of Crohn's and Colitis | August 4, 2020 | Volume: 15 | Issue: 2 | Pages: 273-286

10.1093/ecco-jcc/jjaa166 | PMID 32770196 Get It

Abstract Background and Aims Ileal strictures are the major indication for resective surgery in Crohn’s disease [CD]. We aimed to define ileal gene programmes present at diagnosis and linked with future stricturing behaviour during 5-year follow-up, and to identify potential small molecules to reverse these gene signatures. Methods Antimicrobial serologies and pre-treatment ileal gene expression were assessed in a representative subset of 249 CD patients within the RISK multicentre paediatric CD inception cohort study, including 113 that are unique to this report. These data were used to define genes associated with stricturing behaviour and for model testing to predict stricturing behaviour. A bioinformatics approach to define small molecules which may reverse the stricturing gene signature was applied. Results A total of 19 of the 249 patients developed isolated B2 stricturing behaviour during follow-up, while 218 remained B1 inflammatory. Using deeper RNA sequencing than in our previous report, we have now defined an inflammatory gene signature including an oncostatin M co-expression signature, tightly associated with extra-cellular matrix [ECM] gene expression, in those who developed stricturing complications. We further computationally prioritise small molecules targeting macrophage and fibroblast activation and angiogenesis which may reverse the stricturing gene signature. A model containing ASCA and CBir1 serologies and a refined eight ECM gene set was significantly associated with stricturing development by Year 5 after diagnosis {AUC (area under the curve) (95th CI [confidence interval]) = 0.82 [0.7–0.94)}. Conclusions An ileal gene programme for macrophage and fibroblast activation is linked to stricturing complications in treatment of naïve pediatric CD, and may inform novel small molecule therapeutic approaches.
Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci
Yan, Huihuang , Tian, Shulan , Kleinstern, Geffen , Wang, Zhiquan , Lee, Jeong‐Heon , Cerhan, James R. , Braggio, Esteban , Boddicker, Nicholas J, Cerhan, James R , Lee, Jeong-Heon , Braggio, Esteban , Boddicker, Nicholas , Kay, Neil E. , Slager, Susan L. , Wang, Zhiquan

Mayo Clinic

Human Molecular Genetics | August 3, 2020 | Volume: 29 | Issue: 16 | Pages: 2761-2774

10.1093/hmg/ddaa165 | PMID 32744316 Get It

Abstract Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries. It has a strong genetic basis, showing a ~ 8-fold increased risk of CLL in first-degree relatives. Genome-wide association studies (GWAS) have identified 41 risk variants across 41 loci. However, for a majority of the loci, the functional variants and the mechanisms underlying their causal roles remain undefined. Here, we examined the genetic and epigenetic features associated with 12 index variants, along with any correlated (r2 ≥ 0.5) variants, at the CLL risk loci located outside of gene promoters. Based on publicly available ChIP-seq and chromatin accessibility data as well as our own ChIP-seq data from CLL patients, we identified six candidate functional variants at six loci and at least two candidate functional variants at each of the remaining six loci. The functional variants are predominantly located within enhancers or super-enhancers, including bi-directionally transcribed enhancers, which are often restricted to immune cell types. Furthermore, we found that, at 78% of the functional variants, the alternative alleles altered the transcription factor binding motifs or histone modifications, indicating the involvement of these variants in the change of local chromatin state. Finally, the enhancers carrying functional variants physically interacted with genes enriched in the type I interferon signaling pathway, apoptosis, or TP53 network that are known to play key roles in CLL. These results support the regulatory roles for inherited noncoding variants in the pathogenesis of CLL.
Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons
Mohan, Radhe , Liu, Amy , Brown, Paul D. , Mahajan, Anita , Dinh, Jeffrey, Chung, Caroline , McAvoy, Sarah , McAleer, Mary Frances , Ghia, Amol J. , Zhu, Cong , Sulman, Erik P. , Heimberger, Amy B. , McGovern, Susan L. , Ellsworth, Susannah G. , Grosshans, David R. , Sulman, Erik P , Lin, Steven H. , Li, Jing , Groot, John de , Heimberger, Amy B. , Grassberger, Clemens , Shih, Helen A.

Mayo Clinic

Neuro-Oncology | July 31, 2020 | Volume: 23 | Issue: 2 | Pages: 284-294

10.1093/neuonc/noaa182 | PMID 32750703 Get It

Abstract Background We investigated differences in radiation-induced grade 3+ lymphopenia (G3+L), defined as an absolute lymphocyte count (ALC) nadir of <500 cells/µL, after proton therapy (PT) or X-ray (photon) therapy (XRT) for patients with glioblastoma (GBM). Methods Patients enrolled in a randomized phase II trial received PT (n = 28) or XRT (n = 56) concomitantly with temozolomide. ALC was measured before, weekly during, and within 1 month after radiotherapy. Whole-brain mean dose (WBMD) and brain dose-volume indices were extracted from planned dose distributions. Univariate and multivariate logistic regression analyses were used to identify independent predictive variables. The resulting model was evaluated using receiver operating characteristic (ROC) curve analysis. Results Rates of G3+L were lower in men (7/47 [15%]) versus women (19/37 [51%]) (P < 0.001), and for PT (4/28 [14%]) versus XRT (22/56 [39%]) (P = 0.024). G3+L was significantly associated with baseline ALC, WBMD, and brain volumes receiving 5‒40 Gy(relative biological effectiveness [RBE]) or higher (ie, V5 through V40). Stepwise multivariate logistic regression analysis identified being female (odds ratio [OR] 6.2, 95% confidence interval [CI]: 1.95‒22.4, P = 0.003), baseline ALC (OR 0.18, 95% CI: 0.05‒0.51, P = 0.003), and whole-brain V20 (OR 1.07, 95% CI: 1.03‒1.13, P = 0.002) as the strongest predictors. ROC analysis yielded an area under the curve of 0.86 (95% CI: 0.79–0.94) for the final G3+L prediction model. Conclusions Sex, baseline ALC, and whole-brain V20 were the strongest predictors of G3+L for patients with GBM treated with radiation and temozolomide. PT reduced brain volumes receiving low and intermediate doses and, consequently, reduced G3+L.
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer
Eastham, James A., Halabi, Susan , Monk, J. Paul, Beltran, Himisha , Evans, Christopher P. , Clinton, Steven K. , Watt, Colleen, Sanda, Martin G. , Hahn, Olwen, Taplin, Mary-Ellen, Parsons, J. Kellogg , Mohler, James L. , Hillman, David W. , Halabi, Susan , Heller, Glenn , Gleave, Martin , Szmulewitz, Russell Z , Coleman, Jonathan , George, Saby , Taplin, Mary‐Ellen , Small, Eric J. , Morris, Michael J.

Mayo Clinic

Journal of Clinical Oncology | July 24, 2020 | Volume: 38 | Issue: 26 | Pages: 3042-3050

10.1200/jco.20.00315 | PMID 32706639 Get It

PURPOSE Radical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would improve biochemical progression–free survival (BPFS) over RP alone. PATIENTS AND METHODS Men with clinically localized, high-risk PC were assigned to RP alone or neoadjuvant CHT with androgen deprivation plus docetaxel (75 mg/m 2 body surface area every 3 weeks for 6 cycles) and RP. The primary end point was 3-year BPFS. Biochemical failure was defined as a serum prostate-specific antigen level > 0.2 ng/mL that increased on 2 consecutive occasions that were at least 3 months apart. Secondary end points included 5-year BPFS, overall BPFS, local recurrence, metastasis-free survival (MFS), PC-specific mortality, and overall survival (OS). RESULTS In total, 788 men were randomly assigned. Median follow-up time was 6.1 years. The overall rates of grade 3 and 4 adverse events during chemotherapy were 26% and 19%, respectively. No difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respectively; 95% CI for the difference, −0.01 to 0.11; P = .11). Neoadjuvant CHT was associated with improved overall BPFS (hazard ratio [HR], 0.69; 95% CI, 0.48 to 0.99), improved MFS (HR, 0.70; 95% CI, 0.51 to 0.95), and improved OS (HR, 0.61; 95% CI, 0.40 to 0.94) compared with RP alone. CONCLUSION The primary study end point, 3-year BPFS, was not met. Although some improvement was seen in secondary end points, any potential benefit must be weighed against toxicity. Our data do not support the routine use of neoadjuvant CHT and RP in patients with clinically localized, high-risk PC at this time.
An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2 -Catecholaminergic Polymorphic Ventricular Tachycardia
Ng, Kevin, Titus, Erron W. , Lieve, Krystien V.V. , Roston, Thomas M. , Mazzanti, Andrea , Deiter, Fred , Ingles, Jodie , Till, Jan , Robyns, Tomas , Connors, Sean P., Pang, B. , Bos, J. Martijn , Duffett, Stephen A. , Maltret, Alice , Green, Martin S. , Rutberg, Julie, Balaji, Seshadri , Cadrin‐Tourigny, Julia , Orland, Kate M. , Knight, Linda M., Brateng, Caitlin, Wu, Jeremy , Tang, Anthony , Skanes, Allan C. , Manlucu, Jaimie , January, Craig T., Collins, Kathryn K. , Maginot, Kathleen R., Fischbach, Peter , Etheridge, Susan P. , Eckhardt, Lee L. , Hamilton, Robert M. , Ackerman, Michael J. , Rosés‐Noguer, Ferran , Semsarian, Christopher , Jura, Natalia , Priori, Silvia G. , Sanatani, Shubhayan , Wilde, Arthur A.M. , Deo, Rahul C. , Roberts, Jason D. , Eckhardt, Lee L , Bos, Johan M , Robyns, Tomas , Sanatani, Shubhayan , Hamilton, Robert , Rosés-Noguer, Ferran , Mazzanti, Andrea , Cadrin-Tourigny, Julia , Ingles, Jodie , Priori, Silvia , Lieve, Krystien V , Denjoy, Isabelle , Connors, Sean P., Steinberg, Christian , Abrams, Dominic J. , Scheinman, Melvin M , Werf, Christian van der , Knight, Linda M., Healey, Jeff S. , Krahn, Andrew D. , Leenhardt, Antoine , Gollob, Michael H.

Mayo Clinic

Circulation | July 22, 2020 | Volume: 142 | Issue: 10 | Pages: 932-947

10.1161/circulationaha.120.045723 | PMID 32693635 Get It

Background: Genetic variants in calsequestrin-2 ( CASQ2 ) cause an autosomal recessive form of catecholaminergic polymorphic ventricular tachycardia (CPVT), although isolated reports have identified arrhythmic phenotypes among heterozygotes. Improved insight into the inheritance patterns, arrhythmic risks, and molecular mechanisms of CASQ2 -CPVT was sought through an international multicenter collaboration. Methods: Genotype-phenotype segregation in CASQ2 -CPVT families was assessed, and the impact of genotype on arrhythmic risk was evaluated using Cox regression models. Putative dominant CASQ2 missense variants and the established recessive CASQ2-p.R33Q variant were evaluated using oligomerization assays and their locations mapped to a recent CASQ2 filament structure. Results: A total of 112 individuals, including 36 CPVT probands (24 homozygotes/compound heterozygotes and 12 heterozygotes) and 76 family members possessing at least 1 presumed pathogenic CASQ2 variant, were identified. Among CASQ2 homozygotes and compound heterozygotes, clinical penetrance was 97.1% and 26 of 34 (76.5%) individuals had experienced a potentially fatal arrhythmic event with a median age of onset of 7 years (95% CI, 6–11). Fifty-one of 66 CASQ2 heterozygous family members had undergone clinical evaluation, and 17 of 51 (33.3%) met diagnostic criteria for CPVT. Relative to CASQ2 heterozygotes, CASQ2 homozygote/compound heterozygote genotype status in probands was associated with a 3.2-fold (95% CI, 1.3–8.0; P =0.013) increased hazard of a composite of cardiac syncope, aborted cardiac arrest, and sudden cardiac death, but a 38.8-fold (95% CI, 5.6–269.1; P <0.001) increased hazard in genotype-positive family members. In vitro turbidity assays revealed that p.R33Q and all 6 candidate dominant CASQ2 missense variants evaluated exhibited filamentation defects, but only p.R33Q convincingly failed to dimerize. Structural analysis revealed that 3 of these 6 putative dominant negative missense variants localized to an electronegative pocket considered critical for back-to-back binding of dimers. Conclusions: This international multicenter study of CASQ2 -CPVT redefines its heritability and confirms that pathogenic heterozygous CASQ2 variants may manifest with a CPVT phenotype, indicating a need to clinically screen these individuals. A dominant mode of inheritance appears intrinsic to certain missense variants because of their location and function within the CASQ2 filament structure.
Vascular dysfunction in aged mice contributes to persistent lung fibrosis
Caporarello, Nunzia , Meridew, Jeffrey A., Aravamudhan, Aja, Jones, Dakota L. , Austin, Susan A., Pham, Tho X., Haak, Andrew J. , Choi, Kyoung Moo , Tan, Qi , Haresi, Adil J. , Huang, Steven K. , Katušić, Zvonimir S. , Tschumperlin, Daniel J. , Ligresti, Giovanni , Moo Choi, Kyoung, Caporarello, Nunzia

Mayo Clinic

Aging Cell | July 21, 2020 | Volume: 19 | Issue: 8 | Pages: No page available

10.1111/acel.13196 | PMID 32691484 Get It

Abstract Idiopathic pulmonary fibrosis (IPF) is a progressive disease thought to result from impaired lung repair following injury and is strongly associated with aging. While vascular alterations have been associated with IPF previously, the contribution of lung vasculature during injury resolution and fibrosis is not well understood. To compare the role of endothelial cells (ECs) in resolving and non‐resolving models of lung fibrosis, we applied bleomycin intratracheally to young and aged mice. We found that injury in aged mice elicited capillary rarefaction, while injury in young mice resulted in increased capillary density. ECs from the lungs of injured aged mice relative to young mice demonstrated elevated pro‐fibrotic and reduced vascular homeostasis gene expression. Among the latter, Nos3 (encoding the enzyme endothelial nitric oxide synthase, eNOS) was transiently upregulated in lung ECs from young but not aged mice following injury. Young mice deficient in eNOS recapitulated the non‐resolving lung fibrosis observed in aged animals following injury, suggesting that eNOS directly participates in lung fibrosis resolution. Activation of the NO receptor soluble guanylate cyclase in human lung fibroblasts reduced TGFβ‐induced pro‐fibrotic gene and protein expression. Additionally, loss of eNOS in human lung ECs reduced the suppression of TGFβ‐induced lung fibroblast activation in 2D and 3D co‐cultures. Altogether, our results demonstrate that persistent lung fibrosis in aged mice is accompanied by capillary rarefaction, loss of EC identity, and impaired eNOS expression. Targeting vascular function may thus be critical to promote lung repair and fibrosis resolution in aging and IPF.
The neurosurgery residency interview: assessing applicant perspectives on question content, utility, and stress
Limoges, Natalie , Yengo‐Kahn, Aaron M. , Graffeo, Christopher S. , Chambless, Lola B. , Durham, Susan, Zuckerman, Scott L. , Chitale, Rohan V , Mocco, J

Mayo Clinic

Journal of Neurosurgery | July 17, 2020 | Volume: 134 | Issue: 6 | Pages: 1974-1982

10.3171/2020.4.jns2046 | PMID 32679566 Get It

OBJECTIVE Residency interviews are integral to the recruitment process yet imperfect. Through surveys of neurosurgery residency applicants, the authors describe interview content and the perceived utility and stress of topics from the applicant’s perspective. METHODS All 2018–2019 neurosurgery resident applicants applying to three particular programs were surveyed. Across 10 interview topics, survey questions assessed topic frequency and the applicant’s opinion of the utility and stress of each topic (Likert scale 1–5). Analyses included descriptive statistics, Spearman’s rank correlation, and logistic regression. RESULTS One hundred thirty-three of 265 surveyed US residency applicants (50%) responded. Extracurricular activities, research, future career, non-medicine interests, and small talk were discussed in all interviews. The least frequent topics included neurosurgical knowledge assessment (79%) and manual dexterity tests (45%). The most useful topics according to respondents were future career objectives (4.78 ± 0.49) and prior research (4.76 ± 0.50); the least useful were neurosurgical knowledge assessment (2.67 ± 1.09) and manual dexterity tests (2.95 ± 1.05). The most stressful topics were neurosurgical knowledge assessment (3.66 ± 1.23) and ethical/behavioral scenarios (2.94 ± 1.28). The utility and stress of manual dexterity tests and neurosurgical knowledge assessments were inversely correlated (r = −0.40, p < 0.01; r = −0.36, p < 0.01), whereas no such correlation existed for ethical/behavioral questions (r = −0.12, p = 0.18), indicating that ethical/behavioral questions may have been stressful but were potentially useful topics. Respondents who attended ≥ 15 interviews were more likely to be asked about the three most stressful topics (each p < 0.05). Respondents with children were less likely to be asked about ethical/behavioral scenarios (OR 0.13, 95% CI 0.03–0.52, p < 0.01). CONCLUSIONS Applicants found several of the most frequently discussed topics to be less useful, indicating a potential disconnect between applicant opinion and the faculty’s preferred questions. Ethical/behavioral scenarios were rated as stressful but still useful, representing a potentially worthwhile type of question. These data provide several avenues for potential standardization and improvement of the interview process.
A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers
Powers, Jacquelyn , Pinto, Emília M. , Barnoud, Thibaut , Leung, Jessica C. , Martynyuk, Tetyana , Kossenkov, Andrew V. , Philips, Aaron H., Desai, Heena , Hausler, Ryan , Le, Anh N. , Pyle, Louise C. , Zelley, Kristin , Nathanson, Katherine L. , Slavin, Thomas P. , Weitzel, Jeffrey N. , Stopfer, Jill E. , Offit, Kenneth , Dolinsky, Jill S. , Gutierrez, Stephanie, McGoldrick, Kelly , Levin, Brooke , Edelman, Morris, Levy, Carolyn Fein , Spunt, Sheri L. , Zambetti, Gerard P. , Li, Marilyn M , MacFarland, Suzanne P , Pyle, Louise C , Zelley, Kristin , Domchek, Susan M , Weitzel, Jeffrey N , Garber, J. E. , Joseph, Vijai , Levin, Brooke , Levy, Carolyn Fein , Spunt, Sheri L , Nathanson, Katherine L , Kelly, Gregory, Domchek, Susan M. , Garber, Judy E. , Vijai, Joseph , Couch, Fergus J. , Kriwacki, Richard W. , Ribeiro, Raul C , Murphy, Maureen E. , Maxwell, Kara N.

Mayo Clinic

Cancer Research | July 16, 2020 | Volume: 80 | Issue: 17 | Pages: 3732-3744

10.1158/0008-5472.can-20-1390 | PMID 32675277 Get It

Abstract Germline mutations in TP53 cause a rare high penetrance cancer syndrome, Li–Fraumeni syndrome (LFS). Here, we identified a rare TP53 tetramerization domain missense mutation, c.1000G&gt;C;p.G334R, in a family with multiple late-onset LFS-spectrum cancers. Twenty additional c.1000G&gt;C probands and one c.1000G&gt;A proband were identified, and available tumors showed biallelic somatic inactivation of TP53. The majority of families were of Ashkenazi Jewish descent, and the TP53 c.1000G&gt;C allele was found on a commonly inherited chromosome 17p13.1 haplotype. Transient transfection of the p.G334R allele conferred a mild defect in colony suppression assays. Lymphoblastoid cell lines from the index family in comparison with TP53 normal lines showed that although classical p53 target gene activation was maintained, a subset of p53 target genes (including PCLO, PLTP, PLXNB3, and LCN15) showed defective transactivation when treated with Nutlin-3a. Structural analysis demonstrated thermal instability of the G334R-mutant tetramer, and the G334R-mutant protein showed increased preponderance of mutant conformation. Clinical case review in comparison with classic LFS cohorts demonstrated similar rates of pediatric adrenocortical tumors and other LFS component cancers, but the latter at significantly later ages of onset. Our data show that TP53 c.1000G&gt;C;p.G334R is found predominantly in Ashkenazi Jewish individuals, causes a mild defect in p53 function, and leads to low penetrance LFS. Significance: TP53 c.1000C&gt;G;p.G334R is a pathogenic, Ashkenazi Jewish–predominant mutation associated with a familial multiple cancer syndrome in which carriers should undergo screening and preventive measures to reduce cancer risk.
Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer’s disease
Vermunt, Lisa , Dicks, Ellen , Wang, Guoqiao , Dincer, Aylin , Flores, Shaney , Keefe, Sarah , Berman, Sarah , Cash, David M. , Chhatwal, Jasmeer P. , Cruchaga, Carlos , Fox, Nick C. , Graff‐Radford, Neill R. , Hassenstab, Jason , Laske, Christoph , Xiong, Chengjie , Masters, Colin L. , Mori, Hiroshi , Morris, John C. , Noble, James M. , Perrin, Richard J. , Visser, Pieter Jelle , Bateman, Randall J. , Gordon, Brian A. , (DIAN), Dominantly Inherited Alzheimer Network, Amtashar, Fatima, Bodge, Courtney, Brandon, Susan E. , Buck, Jill , Buckles, Virginia, Chea, Sochenda, Chrem, Patricio, Chui, Helena C., Cinco, Jake, Jack, Clifford, D’Mello, Mirelle , Donahue, Tamara, Douglas, Jane, Edigo, Noelia, Erekin-Taner, Nilufer, Fagan, Anne M. , Farlow, Marty, Farrar, Angela, Feldman, Howard , Flynn, Gigi, Franklin, Erin , Gant, Cortaiga, Gardener, Samantha L. , Gray, Julia, Gurney, Jenny , Hassenstab, Jason, Hirohara, Mie, Hornbeck, Russ C. , DiBari, Siri Houeland, Ikonomović, Snežana, Jerome, Gina, Klunk, William E. , Kuder-Buletta, Elke, Marcus, Daniel S. , Mason, Neal Scott, Maue-Dreyfus, Denise, Montoya, Lucy, Nagamatsu, Akem, Neimeyer, Katie, Norton, Joanne, Raichle, Marc, Ringman, John M. , Roh, Jee Hoon , Shiroto, Tomoyo, Sigurdson, Wendy, Sparks, Paige, Swisher, Laura, Taddei, Kevin , Wang, Peter, Weiner, Mike, Wolfsberger, Mary, Xiong, Chengjie, Tijms, Betty M , Gordon, Brian A , Cruchaga, Carlos , Bateman, Randall J , Masters, Colin L , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Roh, Jee Hoon , Cash, David M , Feldman, Howard H , Berman, Sarah , Ghetti, Bernardino , Karch, Celeste M. , McDade, Eric , Schofield, Peter R. , Xiong, Chengjie , Scheltens, Philip , Benzinger, Tammie L.S. , Tijms, Betty M. , (DIAN), Dominantly Inherited Alzheimer Network, Allegri, Ricardo , Brandon, Susan, Brooks, William S. , Buck, Jill, Chui, Helena C. , Fujii, Hisako , Goate, Alison , Goldman, Jill , Hassenstab, Jason, Holtzman, David M. , Ikeuchi, Takeshi , Jucker, Mathias , Kasuga, Kensaku , Kawarabayashi, Takeshi , Koeppe, Robert A. , Martins, Ralph N. , Shimada, Hiroyuki , Shoji, Mikio , Sohrabi, Hamid R. , Suzuki, Kazushi , Wang, Jen Chin C. , Xiong, Chengjie, Xu, Xiong, Noble, James M

Mayo Clinic

Brain Communications | July 15, 2020 | Volume: 2 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcaa102 | PMID 32954344 Get It

Abstract Structural grey matter covariance networks provide an individual quantification of morphological patterns in the brain. The network integrity is disrupted in sporadic Alzheimer’s disease, and network properties show associations with the level of amyloid pathology and cognitive decline. Therefore, these network properties might be disease progression markers. However, it remains unclear when and how grey matter network integrity changes with disease progression. We investigated these questions in autosomal dominant Alzheimer’s disease mutation carriers, whose conserved age at dementia onset allows individual staging based upon their estimated years to symptom onset. From the Dominantly Inherited Alzheimer Network observational cohort, we selected T1-weighted MRI scans from 269 mutation carriers and 170 non-carriers (mean age 38 ± 15 years, mean estimated years to symptom onset −9 ± 11), of whom 237 had longitudinal scans with a mean follow-up of 3.0 years. Single-subject grey matter networks were extracted, and we calculated for each individual the network properties which describe the network topology, including the size, clustering, path length and small worldness. We determined at which time point mutation carriers and non-carriers diverged for global and regional grey matter network metrics, both cross-sectionally and for rate of change over time. Based on cross-sectional data, the earliest difference was observed in normalized path length, which was decreased for mutation carriers in the precuneus area at 13 years and on a global level 12 years before estimated symptom onset. Based on longitudinal data, we found the earliest difference between groups on a global level 6 years before symptom onset, with a greater rate of decline of network size for mutation carriers. We further compared grey matter network small worldness with established biomarkers for Alzheimer disease (i.e. amyloid accumulation, cortical thickness, brain metabolism and cognitive function). We found that greater amyloid accumulation at baseline was associated with faster decline of small worldness over time, and decline in grey matter network measures over time was accompanied by decline in brain metabolism, cortical thinning and cognitive decline. In summary, network measures decline in autosomal dominant Alzheimer’s disease, which is alike sporadic Alzheimer’s disease, and the properties show decline over time prior to estimated symptom onset. These data suggest that single-subject networks properties obtained from structural MRI scans form an additional non-invasive tool for understanding the substrate of cognitive decline and measuring progression from preclinical to severe clinical stages of Alzheimer’s disease.